Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

2 Sept 2020

Abstract excerpt

BACKGROUND: Cisplatin is a first-line drug for the treatment of human non-small cell lung cancer (NSCLC); however, the majority of patients will develop drug resistance after treatment. In order to overcome cisplatin resistance, it is important to understand the mechanisms underlying the resistance. METHODS: A gene microarray was used to screen for genes related to cisplatin resistance in NSCLC cell lines....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cerebrovascular and genetic disorders
Share to Histone Deacetylase Inhibitors Research
Share to Intracerebral and Subarachnoid Hemorrhage Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32878625
DOI: 10.1186/s12943-020-01256-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancerPMID 32878625Read ↗

Regulation of cisplatin resistance in lung cancer by epigenetic mechanismsSemantic proximity Read ↗

Role of long non-coding RNA in drug resistance in non-small cell lung cancer.Semantic proximity Read ↗

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Semantic proximity Read ↗

HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cell‐Like PropertiesSemantic proximity Read ↗

Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer.Semantic proximity Read ↗

Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung CancerSemantic proximity Read ↗

Epithelial–mesenchymal transition and cancer stem cells: A route to acquired cisplatin resistance through epigenetics in HNSCCSemantic proximity Read ↗

Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2Semantic proximity Read ↗

MicroRNAs as Regulators of Cisplatin Resistance in Lung CancerSemantic proximity Read ↗

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read ↗

The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancerSemantic proximity Read ↗

Increased ABCC2 expression predicts cisplatin resistance in non‐small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.